bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 2 from Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate
Authors: Lee Oukseub , Sullivan Megan E. , Xu Yanfei , Rogers Chiara , Muzzio Miguel , Helenowski Irene , Shidfar Ali , Zeng Zexian , Singhal Hari , Jovanovic Borko , Hansen Nora , Bethke Kevin P. , Gann Peter H. , Gradishar William , Kim J. Julie , Clare Susan E. , Khan Seema A.
Published: April 2023

Supplemental Figure 2. Ki67 Change relative to treatment duration. There was no significant correlation between change in Ki67 and treatment duration, in either TPA or placebo arms.
Supplemental Table 3 from Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate
Authors: Lee Oukseub , Sullivan Megan E. , Xu Yanfei , Rogers Chiara , Muzzio Miguel , Helenowski Irene , Shidfar Ali , Zeng Zexian , Singhal Hari , Jovanovic Borko , Hansen Nora , Bethke Kevin P. , Gann Peter H. , Gradishar William , Kim J. Julie , Clare Susan E. , Khan Seema A.
Published: April 2023

Supplemental table 3. Nanostring nCounter Differential gene expression (excel file) -uploading separately.
Supplementary Table S1 from Long Noncoding RNA SChLAP1 Forms a Growth-Promoting Complex with HNRNPL in Human Glioblastoma through Stabilization of ACTN4 and Activation of NF-κB Signaling
Authors: Ji Jianxiong , Xu Ran , Ding Kaikai , Bao Guoqing , Zhang Xin , Huang Bin , Wang Xinyu , Martinez Aurora , Wang Xiuying , Li Gang , Miletic Hrvoje , Thorsen Frits , Bjerkvig Rolf , Xiang Lei , Han Bo , Chen Anjing , Li Xingang , Wang Jian
Published: April 2023

Clinical data for individual patients
Figure S2 from Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
Authors: Yu Jiayi , Yan Junya , Guo Qian , Chi Zhihong , Tang Bixia , Zheng Bin , Yu Jinyu , Yin Ting , Cheng Zhiyuan , Wu Xiaowen , Yu Huan , Dai Jie , Sheng Xinan , Si Lu , Cui Chuanliang , Bai Xue , Mao Lili , Lian Bin , Wang Xuan , Yan Xieqia , Li Siming , Zhou Li , Flaherty Keith T. , Guo Jun , Kong Yan
Published: April 2023

Supplementary Figure S2. The PD-1 staining of C57BL/6-hPD-1 mice.
Supplementary Text from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
Authors: Montanuy Helena , Martínez-Barriocanal Águeda , Antonio Casado José , Rovirosa Llorenç , Ramírez Maria José , Nieto Rocío , Carrascoso-Rubio Carlos , Riera Pau , González Alan , Lerma Enrique , Lasa Adriana , Carreras-Puigvert Jordi , Helleday Thomas , Bueren Juan A. , Arango Diego , Minguillón Jordi , Surrallés Jordi
Published: April 2023

Supplementary Text
Supplementary Data from AI-Assisted In Situ Detection of Human Glioma Infiltration Using a Novel Computational Method for Optical Coherence Tomography
Authors: Juarez-Chambi Ronald M. , Kut Carmen , Rico-Jimenez Jose J. , Chaichana Kaisorn L. , Xi Jiefeng , Campos-Delgado Daniel U. , Rodriguez Fausto J. , Quinones-Hinojosa Alfredo , Li Xingde , Jo Javier A.
Published: April 2023

This document contains suplementary data (Figure S1, Figure S2, Table S1, and Table S2). Each of these Figures and Tables has a detailed explanation for their calculations
Supplementary Figure 6 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
Authors: Montanuy Helena , Martínez-Barriocanal Águeda , Antonio Casado José , Rovirosa Llorenç , Ramírez Maria José , Nieto Rocío , Carrascoso-Rubio Carlos , Riera Pau , González Alan , Lerma Enrique , Lasa Adriana , Carreras-Puigvert Jordi , Helleday Thomas , Bueren Juan A. , Arango Diego , Minguillón Jordi , Surrallés Jordi
Published: April 2023

Figure S6. Additional data on gefitinib and afatinib toxicity analysis in WT and Fanca-deficient mice.
Supplementary Figure 1 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
Authors: Montanuy Helena , Martínez-Barriocanal Águeda , Antonio Casado José , Rovirosa Llorenç , Ramírez Maria José , Nieto Rocío , Carrascoso-Rubio Carlos , Riera Pau , González Alan , Lerma Enrique , Lasa Adriana , Carreras-Puigvert Jordi , Helleday Thomas , Bueren Juan A. , Arango Diego , Minguillón Jordi , Surrallés Jordi
Published: April 2023

Figure S1. Additional data from high content screening and validation
Supplementary Data from Molecular Classification of Lymph Node Metastases Subtypes Predict for Survival in Head and Neck Cancer
Authors: Huang Lei , David Odile , Cabay Robert J. , Valyi-Nagy Klara , Macias Virgilia , Zhong Rong , Wenig Barry , Feldman Lawrence , Weichselbaum Ralph , Spiotto Michael T.
Published: April 2023

Supplemental Methods, Supplemental Tables 1, 3, 4, 6, 7, 8, Supplemental Figures 1-12 Supplemental Table 1. Overall patient characteristics. Supplemental Table 3. Patient Characteristics by lymph node molecular classification. Supplemental Table 4. Univariate and multivariate analysis for locoregional control. Supplemental Table 7. Accuracy of existing classifiers to predict Group 2 LNM subtype. Supplemental Table 8. 73 gene classifier Supplemental Figure 1. Patient selection. Supplemental Figure 2. Metrics of the 73 gene classifier. (A) Metrics of 73 gene classifier. (B) Misclassification error for C2 and C13 groups. (C) Misclassification of entire classifier. Supplemental Figure 3. Outcomes in HNSCC cohort.Kaplan-Meier analysis of: (A) Locoregional control. (B) Local-only control. (C) Relapse free survival. (D) Regional control. (E) Distant control. (F) Overall survival. Supplemental Figure 4. Outcomes by molecular subtypes of LNMs.Kaplan-Meier analysis of: (A) Regional control. (B) Distant control. Supplementary Figure 5: DEmiRNAsin LNMs subtypes. Supplemental Figure 6. Consensus clustering of pairwise DEGs for other predefined cluster numbers does not identify other LNMs subtypes that predict for disease recurrence. Supplemental Figure 7. Enrichment of KEGG pathways in LNMs subtypes. Supplemental Figure 8. Estimated abundance of immune cells. Supplemental Figure 9. LNMs subtypes cluster separately from non-metastatic lymph nodes in the same cohort. Supplemental Figure 10. LNMs subtypes cluster separately from normal lymph nodes derived from publically available microarray databases. Supplemental Figure 11. The transcriptome of lymph node metastasis better predicts for patients at higher risk of relapse or death. Supplemental Figure 12. Receiver-Operator Curve for 73 gene LNM-classifier.
Supplementary Table 3 from Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types
Authors: Chen William S. , Alshalalfa Mohammed , Zhao Shuang G. , Liu Yang , Mahal Brandon A. , Quigley David A. , Wei Ting , Davicioni Elai , Rebbeck Timothy R. , Kantoff Philip W. , Maher Christopher A. , Knudsen Karen E. , Small Eric J. , Nguyen Paul L. , Feng Felix Y.
Published: April 2023

Genes differentially expressed in RB1 loss tumors with two or more RB1 mutations
Figure S1 from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma
Authors: Yan Zi-Xun , Li Li , Wang Wen , OuYang Bin-Shen , Cheng Shu , Wang Li , Wu Wen , Xu Peng-Peng , Muftuoglu Muharrem , Hao Ming , Yang Su , Zhang Mu-Chen , Zheng Zhong , Li James , Zhao Wei-Li
Published: April 2023

Supplementary Figure S1. PET-CT and CT evaluation of the partial remission patients before CAR T treatment and on Day 29 after treatment.
Supplementary Table 1 from Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types
Authors: Chen William S. , Alshalalfa Mohammed , Zhao Shuang G. , Liu Yang , Mahal Brandon A. , Quigley David A. , Wei Ting , Davicioni Elai , Rebbeck Timothy R. , Kantoff Philip W. , Maher Christopher A. , Knudsen Karen E. , Small Eric J. , Nguyen Paul L. , Feng Felix Y.
Published: April 2023

RBS gene signature
Supplementary Data from Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases
Authors: Morikawa Aki , de Stanchina Elisa , Pentsova Elena , Kemeny Margaret M. , Li Bob T. , Tang Kendrick , Patil Sujata , Fleisher Martin , Van Poznak Catherine , Norton Larry , Seidman Andrew D.
Published: April 2023

Supplemental preclinical data background
Supplementary Figure Legends from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
Authors: Tuscano Joseph M. , Maverakis Emanual , Groshen Susan , Tsao-Wei Denice , Luxardi Guillaume , Merleev Alexander A. , Beaven Anne , DiPersio John F. , Popplewell Leslie , Chen Robert , Kirschbaum Mark , Schroeder Mark A. , Newman Edward M.
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 3 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
Authors: Tuscano Joseph M. , Maverakis Emanual , Groshen Susan , Tsao-Wei Denice , Luxardi Guillaume , Merleev Alexander A. , Beaven Anne , DiPersio John F. , Popplewell Leslie , Chen Robert , Kirschbaum Mark , Schroeder Mark A. , Newman Edward M.
Published: April 2023

Supplementary Figure 3
Table S1 from A Constitutional Activating MET Mutation Makes the Genetic Link between Malignancies and Chronic Inflammatory Diseases
Authors: El Bouchtaoui Morad , Do Cruzeiro Marcio , Leboeuf Christophe , Loisel-Ferreira Irmine , Fedronie Carèle , Ferreira Chrystophe , Ait El Far Rachida , Ziol Marianne , Espié Marc , Falgarone Géraldine , Cassinat Bruno , Kiladjian Jean-Jacques , Feugeas Jean-Paul , Janin Anne , Bousquet Guilhem
Published: April 2023

Supplementary Table S1
Supplemenary Figure 4 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
Authors: Tuscano Joseph M. , Maverakis Emanual , Groshen Susan , Tsao-Wei Denice , Luxardi Guillaume , Merleev Alexander A. , Beaven Anne , DiPersio John F. , Popplewell Leslie , Chen Robert , Kirschbaum Mark , Schroeder Mark A. , Newman Edward M.
Published: April 2023

Supplemenary Figure 4
Supplementary Tables and Figures from Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes
Authors: Santini Valeria , Valcárcel David , Platzbecker Uwe , Komrokji Rami S. , Cleverly Ann L. , Lahn Michael M. , Janssen Jan , Zhao Yumin , Chiang Alan , Giagounidis Aristoteles , Guba Susan C. , Gueorguieva Ivelina , Girvan Allicia C. , da Silva Ferreira Mariana , Bhagat Tushar D. , Pradhan Kith , Steidl Ulrich , Sridharan Ashwin , Will Britta , Verma Amit
Published: April 2023

Supp Tables and Figs
Methods and figures from ImmunoPET, [64Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model
Authors: Srideshikan Sargur Madabushi , Brooks Jamison , Zuro Darren , Kumar Bijender , Sanchez James , Echavarria Parra Liliana , Orellana Marvin , Vishwasrao Paresh , Nair Indu , Chea Junie , Poku Kofi , Bowles Nicole , Miller Aaron , Ebner Todd , Molnar Justin , Rosenthal Joseph , Vallera Daniel A. , Wong Jeffrey Y.C. , Stein Anthony S. , Colcher David , Shively John E. , Yazaki Paul J. , Hui Susanta K.
Published: April 2023

Supplementary methods and figures
Table S1 and Figure S1 from Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia
Authors: Ma Jun , Zhao Shoujing , Qiao Xinan , Knight Tristan , Edwards Holly , Polin Lisa , Kushner Juiwanna , Dzinic Sijana H. , White Kathryn , Wang Guan , Zhao Lijing , Lin Hai , Wang Yue , Taub Jeffrey W. , Ge Yubin
Published: April 2023

Table S1 shows patient characteristics and Figure S1 shows preliminary efficacy results
Supplementary Table 1 from Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY
Authors: Tagawa Scott T. , Antonarakis Emmanuel S. , Gjyrezi Ada , Galletti Giuseppe , Kim Seaho , Worroll Daniel , Stewart John , Zaher Atef , Szatrowski Ted P. , Ballman Karla V. , Kita Katsuhiro , Tasaki Shinsuke , Bai Yang , Portella Luigi , Kirby Brian J. , Saad Fred , Eisenberger Mario A. , Nanus David M. , Giannakakou Paraskevi
Published: April 2023

ddPCR primer and probe sequences AR, androgen receptor; FL, full length.
Supplementary Materials and Methods from Developing Allogeneic Double-Negative T Cells as a Novel Off-the-Shelf Adoptive Cellular Therapy for Cancer
Authors: Lee Jong Bok , Kang Hyeonjeong , Fang Linan , D'Souza Cheryl , Adeyi Oyedele , Zhang Li
Published: April 2023

Supplementary Materials and Methods
Supplementary Figure 1 from Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY
Authors: Tagawa Scott T. , Antonarakis Emmanuel S. , Gjyrezi Ada , Galletti Giuseppe , Kim Seaho , Worroll Daniel , Stewart John , Zaher Atef , Szatrowski Ted P. , Ballman Karla V. , Kita Katsuhiro , Tasaki Shinsuke , Bai Yang , Portella Luigi , Kirby Brian J. , Saad Fred , Eisenberger Mario A. , Nanus David M. , Giannakakou Paraskevi
Published: April 2023

Assay sensitivity in 22RV1 prostate cancer cells spiked-in healthy donor blood run through the GEDI device. AR-FL (blue) and AR-V7 (red) mRNA expression (#copies per sample) was determined by ddPCR in varying amounts of 22RV1 cells in the presence of healthy donor blood run through the GEDI device. The assay, reliably and reproducibly detects both transcripts in single spiked-in cells. The table below the graph shows the raw data (copy number) for each transcript per condition. Healthy donor blood PBMCs alone were used as a control. AR, androgen receptor; ddPCR, droplet digital polymerase chain reaction; FL, full length; GEDI, geometrically enhanced differential immunocapture; PBMC, peripheral blood mononuclear cell.
Supplementary Data from Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies
Authors: Dylgjeri Emanuela , McNair Christopher , Goodwin Jonathan F. , Raymon Heather K. , McCue Peter A. , Shafi Ayesha A. , Leiby Benjamin E. , de Leeuw Renée , Kothari Vishal , McCann Jennifer J. , Mandigo Amy C. , Chand Saswati N. , Schiewer Matthew J. , Brand Lucas J. , Vasilevskaya Irina , Gordon Nicolas , Laufer Talya S. , Gomella Leonard G. , Lallas Costas D. , Trabulsi Edouard J. , Feng Felix Y. , Filvaroff Ellen H. , Hege Kristin , Rathkopf Dana , Knudsen Karen E.
Published: April 2023

Supplementary Figures 1-6
Table S3 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL–Induced B-Cell Acute Lymphoblastic Leukemia
Authors: Yang Linyu , Qiu Qiang , Tang Minghai , Wang Fang , Yi Yuyao , Yi Dongni , Yang Zhuang , Zhu Zejiang , Zheng Shoujun , Yang Jianhong , Pei Heying , Zheng Li , Chen Yong , Gou Liping , Luo Liya , Deng Xing , Ye Haoyu , Hu Yiguo , Niu Ting , Chen Lijuan
Published: April 2023

PM concentration in tissues after a single intravenous administration to BL-2 bearing mice (Mean {plus minus} SD; n = 4).
Table S2 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL–Induced B-Cell Acute Lymphoblastic Leukemia
Authors: Yang Linyu , Qiu Qiang , Tang Minghai , Wang Fang , Yi Yuyao , Yi Dongni , Yang Zhuang , Zhu Zejiang , Zheng Shoujun , Yang Jianhong , Pei Heying , Zheng Li , Chen Yong , Gou Liping , Luo Liya , Deng Xing , Ye Haoyu , Hu Yiguo , Niu Ting , Chen Lijuan
Published: April 2023

IC50 values of PM and LBH589 against various hematological tumor cell lines.
Figure S1 from Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma
Authors: Katagi Hiroaki , Louis Nundia , Unruh Dusten , Sasaki Takahiro , He Xingyao , Zhang Ali , Ma Quanhong , Piunti Andrea , Shimazu Yosuke , Lamano Jonathan B. , Carcaboso Angel M. , Tian Xiao , Seluanov Andrei , Gorbunova Vera , Laurie Kathryn L. , Kondo Akihide , Wadhwani Nitin R. , Lulla Rishi , Goldman Stewart , Venneti Sriram , Becher Oren J. , Zou Lihua , Shilatifard Ali , Hashizume Rintaro
Published: April 2023

Supplementary Figure S1
Supplementary Tables from Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell–recruiting Antibody Optimized for Cytotoxicity and Cytokine Release
Authors: Zuch de Zafra Christina L. , Fajardo Flordeliza , Zhong Wendy , Bernett Matthew J. , Muchhal Umesh S. , Moore Gregory L. , Stevens Jennitte , Case Ryan , Pearson Joshua T. , Liu Siyuan , McElroy Patricia L. , Canon Jude , Desjarlais John R. , Coxon Angela , Balazs Mercedesz , Nolan-Stevaux Olivier
Published: April 2023

Tables S1 to S6
Table S5 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid Tumors
Authors: Kieran Mark W. , Geoerger Birgit , Dunkel Ira J. , Broniscer Alberto , Hargrave Darren , Hingorani Pooja , Aerts Isabelle , Bertozzi Anne-Isabelle , Cohen Kenneth J. , Hummel Trent R. , Shen Violet , Bouffet Eric , Pratilas Christine A. , Pearson Andrew D.J. , Tseng Lillian , Nebot Noelia , Green Steven , Russo Mark W. , Whitlock James A.
Published: April 2023

Adverse events, suspected to be study drug related, reported by primary system organ class
Supplementary Methods from Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell–recruiting Antibody Optimized for Cytotoxicity and Cytokine Release
Authors: Zuch de Zafra Christina L. , Fajardo Flordeliza , Zhong Wendy , Bernett Matthew J. , Muchhal Umesh S. , Moore Gregory L. , Stevens Jennitte , Case Ryan , Pearson Joshua T. , Liu Siyuan , McElroy Patricia L. , Canon Jude , Desjarlais John R. , Coxon Angela , Balazs Mercedesz , Nolan-Stevaux Olivier
Published: April 2023

Affinity measurements and antibody panels
Table S4 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid Tumors
Authors: Kieran Mark W. , Geoerger Birgit , Dunkel Ira J. , Broniscer Alberto , Hargrave Darren , Hingorani Pooja , Aerts Isabelle , Bertozzi Anne-Isabelle , Cohen Kenneth J. , Hummel Trent R. , Shen Violet , Bouffet Eric , Pratilas Christine A. , Pearson Andrew D.J. , Tseng Lillian , Nebot Noelia , Green Steven , Russo Mark W. , Whitlock James A.
Published: April 2023

Adverse events, regardless of study drug relationship, by preferred term and maximum grade (>20% overall)
Table S3 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid Tumors
Authors: Kieran Mark W. , Geoerger Birgit , Dunkel Ira J. , Broniscer Alberto , Hargrave Darren , Hingorani Pooja , Aerts Isabelle , Bertozzi Anne-Isabelle , Cohen Kenneth J. , Hummel Trent R. , Shen Violet , Bouffet Eric , Pratilas Christine A. , Pearson Andrew D.J. , Tseng Lillian , Nebot Noelia , Green Steven , Russo Mark W. , Whitlock James A.
Published: April 2023

Treatment history
Figure S3 from BRN4 Is a Novel Driver of Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer and Is Selectively Released in Extracellular Vesicles with BRN2
Authors: Bhagirath Divya , Yang Thao Ly , Tabatabai Z. Laura , Majid Shahana , Dahiya Rajvir , Tanaka Yuichiro , Saini Sharanjot
Published: April 2023

Fig. S3 EV-associated BRN2 mediates neuroendocrine differentiation states in prostate cancer
Supplementary figure legend from Leukotriene Synthesis Is Critical for Medulloblastoma Progression
Authors: Du Fang , Yuelling Larra , Lee Eric H. , Wang Yuan , Liao Shengyou , Cheng Yan , Zhang Li , Zheng Chaonan , Peri Suraj , Cai Kathy Q. , Ng Jessica M.Y. , Curran Tom , Li Peng , Yang Zeng-jie
Published: April 2023

Supplementary figure legend
Figure S8 from Leukotriene Synthesis Is Critical for Medulloblastoma Progression
Authors: Du Fang , Yuelling Larra , Lee Eric H. , Wang Yuan , Liao Shengyou , Cheng Yan , Zhang Li , Zheng Chaonan , Peri Suraj , Cai Kathy Q. , Ng Jessica M.Y. , Curran Tom , Li Peng , Yang Zeng-jie
Published: April 2023

Figure S8
Figure S7 from Leukotriene Synthesis Is Critical for Medulloblastoma Progression
Authors: Du Fang , Yuelling Larra , Lee Eric H. , Wang Yuan , Liao Shengyou , Cheng Yan , Zhang Li , Zheng Chaonan , Peri Suraj , Cai Kathy Q. , Ng Jessica M.Y. , Curran Tom , Li Peng , Yang Zeng-jie
Published: April 2023

Figure S7
Figure S5 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma
Authors: Zhang Jiu-Yang , Zhang Pei-Pei , Zhou Wen-Ping , Yu Jia-Yu , Yao Zhi-Hua , Chu Jun-Feng , Yao Shu-Na , Wang Cheng , Lone Waseem , Xia Qing-Xin , Ma Jie , Yang Shu-Jun , Liu Kang-Dong , Dong Zi-Gang , Guo Yong-Jun , Smith Lynette M. , McKeithan Timothy W. , Chan Wing C. , Iqbal Javeed , Liu Yan-Yan
Published: April 2023

Figure S5 shows the influence of L-type calcium channel modulators on rituximab-mediated calcium influx and CD20 expression.(A) Nimodipine weakened rituximab-induced increase of intracellular calcium ions, whereas Bay K8644 enhanced it in OCI-ly3 and OCI-ly7 cell lines (p<0.05). (B) Neither nimodipine nor Bay K8644 influenced CD20 protein expression after treatment of 24 h and 48 h.
Figure S4 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma
Authors: Zhang Jiu-Yang , Zhang Pei-Pei , Zhou Wen-Ping , Yu Jia-Yu , Yao Zhi-Hua , Chu Jun-Feng , Yao Shu-Na , Wang Cheng , Lone Waseem , Xia Qing-Xin , Ma Jie , Yang Shu-Jun , Liu Kang-Dong , Dong Zi-Gang , Guo Yong-Jun , Smith Lynette M. , McKeithan Timothy W. , Chan Wing C. , Iqbal Javeed , Liu Yan-Yan
Published: April 2023

Figure S4 shows CACNA1C and CD20 expression and their association with rituximab response in DLBCL cell lines.(A and B) CACNA1C and CD20 mRNA expression were different among OCI-ly3, OCI-ly7, and OCI-ly8 cell lines (p<0.05). (C-E) CACNA1C and CD20 protein expression were also different among three cell lines detected using flow cytometry and western blot, which concordant with their mRNA expression. (F and G) Rituximab induced significant apoptosis in OCI-ly7 and OCI-ly8 compared to OCI-ly3 cell line (p<0.05).
Figure S3 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma
Authors: Zhang Jiu-Yang , Zhang Pei-Pei , Zhou Wen-Ping , Yu Jia-Yu , Yao Zhi-Hua , Chu Jun-Feng , Yao Shu-Na , Wang Cheng , Lone Waseem , Xia Qing-Xin , Ma Jie , Yang Shu-Jun , Liu Kang-Dong , Dong Zi-Gang , Guo Yong-Jun , Smith Lynette M. , McKeithan Timothy W. , Chan Wing C. , Iqbal Javeed , Liu Yan-Yan
Published: April 2023

Figure S3 shows the survival curve of patients treated by CHOP regimen.There was survival indifference between patients with distinct CACNA1C expression in the setting of CHOP treatment (p>0.05).
Figure S2 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma
Authors: Zhang Jiu-Yang , Zhang Pei-Pei , Zhou Wen-Ping , Yu Jia-Yu , Yao Zhi-Hua , Chu Jun-Feng , Yao Shu-Na , Wang Cheng , Lone Waseem , Xia Qing-Xin , Ma Jie , Yang Shu-Jun , Liu Kang-Dong , Dong Zi-Gang , Guo Yong-Jun , Smith Lynette M. , McKeithan Timothy W. , Chan Wing C. , Iqbal Javeed , Liu Yan-Yan
Published: April 2023

Figure S2 shows probe sets for CACNA1c on HG-U133plus2 platform.
Figure S1 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma
Authors: Zhang Jiu-Yang , Zhang Pei-Pei , Zhou Wen-Ping , Yu Jia-Yu , Yao Zhi-Hua , Chu Jun-Feng , Yao Shu-Na , Wang Cheng , Lone Waseem , Xia Qing-Xin , Ma Jie , Yang Shu-Jun , Liu Kang-Dong , Dong Zi-Gang , Guo Yong-Jun , Smith Lynette M. , McKeithan Timothy W. , Chan Wing C. , Iqbal Javeed , Liu Yan-Yan
Published: April 2023

Figure S1 shows the design of regulating the expression of miRNA-363.(A) The construction of FUA based miRNA-363 lentiviral vector; (B) The scheme of miRNA-363 knockout using CRISPR/Cas9 system.
Figure S14 from Leukotriene Synthesis Is Critical for Medulloblastoma Progression
Authors: Du Fang , Yuelling Larra , Lee Eric H. , Wang Yuan , Liao Shengyou , Cheng Yan , Zhang Li , Zheng Chaonan , Peri Suraj , Cai Kathy Q. , Ng Jessica M.Y. , Curran Tom , Li Peng , Yang Zeng-jie
Published: April 2023

Figure S14
Figure S13 from Leukotriene Synthesis Is Critical for Medulloblastoma Progression
Authors: Du Fang , Yuelling Larra , Lee Eric H. , Wang Yuan , Liao Shengyou , Cheng Yan , Zhang Li , Zheng Chaonan , Peri Suraj , Cai Kathy Q. , Ng Jessica M.Y. , Curran Tom , Li Peng , Yang Zeng-jie
Published: April 2023

Figure S13
Figure S1 from Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses
Authors: Caetano Mauricio S. , Younes Ahmed I. , Barsoumian Hampartsoum B. , Quigley Michael , Menon Hari , Gao Chan , Spires Thomas , Reilly Timothy P. , Cadena Alexandra P. , Cushman Taylor R. , Schoenhals Jonathan E. , Li Ailin , Nguyen Quynh-Nhu , Cortez Maria Angelica , Welsh James W.
Published: April 2023

High dose RT induced higher apoptosis. Mice were inoculated in the right leg with 344SQ for establishment of primary tumor. Tumors were treated locally by intermediate dose RT (15 Gy in three 5-Gy fractions) or High dose RT (36 Gy in three 12-Gy fractions). Tumors were harvested 7 days after the last fraction of RT then sectioned for Immunohistochemistry using Caspase-3 staining.
Figure S11 from Leukotriene Synthesis Is Critical for Medulloblastoma Progression
Authors: Du Fang , Yuelling Larra , Lee Eric H. , Wang Yuan , Liao Shengyou , Cheng Yan , Zhang Li , Zheng Chaonan , Peri Suraj , Cai Kathy Q. , Ng Jessica M.Y. , Curran Tom , Li Peng , Yang Zeng-jie
Published: April 2023

Figure S11
Supplementary Tables from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
Authors: Leleu Xavier , Fouquet Guillemette , Richez Valentine , Guidez Stéphanie , Duhamel Alain , Machuron François , Karlin Lionel , Kolb Brigitte , Tiab Mourad , Araujo Carla , Meuleman Nathalie , Malfuson Jean-Valère , Bourquard Pascal , Lenain Pascal , Roussel Murielle , Jaccard Arnaud , Pétillon Marie-Odile , Belhadj-Merzoug Karim , Lepeu Gérard , Chrétien Marie-Lorraine , Fontan Jean , Rodon Philippe , Schmitt Anna , Offner Fritz , Voillat Laurent , Cereja Sophie , Kuhnowski Frédérique , Rigaudeau Sophie , Decaux Olivier , Humbrecht-Kraut Catherine , Frayfer Jamile , Fitoussi Olivier , Roos-Weil Damien , Eisenmann Jean-Claude , Dorvaux Véronique , Voog Eric G. , Attal Michel , Moreau Philippe , Avet-Loiseau Hervé , Hulin Cyrille , Facon Thierry
Published: April 2023

Supplementary tables 1 to 5
Figure S1 from Leukotriene Synthesis Is Critical for Medulloblastoma Progression
Authors: Du Fang , Yuelling Larra , Lee Eric H. , Wang Yuan , Liao Shengyou , Cheng Yan , Zhang Li , Zheng Chaonan , Peri Suraj , Cai Kathy Q. , Ng Jessica M.Y. , Curran Tom , Li Peng , Yang Zeng-jie
Published: April 2023

Figure S1
Supplementary Table 1 from Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric Study
Authors: Kang Shin-Ae , Guan Jye Swei , Tan Hock Jin , Chu Tinghine , Thike Aye Aye , Bernadó Cristina , Arribas Joaquín , Wong Chow Yin , Tan Puay Hoon , Gudi Mihir , Putti Thomas Choudary , Sohn Joohyuk , Lim Swee Ho , Lee Soo Chin , Lim Yoon Pin
Published: April 2023

Supplementary Table 1
Supplemental Tables and Figures from Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs
Authors: Hurvitz Sara A. , O'Shaughnessy Joyce , Mason Ginny , Yardley Denise A. , Jahanzeb Mohammad , Brufsky Adam , Rugo Hope S. , Swain Sandra M. , Kaufman Peter A. , Tripathy Debu , Chu Laura , Li Haocheng , Antao Vincent , Cobleigh Melody
Published: April 2023

This file includes Supplemental Table 1, Supplemental Table 2, Supplemental Table 3, Supplemental Table 4, Supplemental Table 5, Supplemental Figure 1, Supplemental Figure 2, Supplemental Figure 3, Supplemental Figure 4, and Supplemental Figure 5.
Figure S2 from Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial
Authors: Li Li , Jiang Liyan , Wang Yubo , Zhao Yizhuo , Zhang Xiao-Ju , Wu Guoming , Zhou Xiangdong , Sun Jianguo , Bai Jun , Ren Biyong , Tian Kun , Xu Zhi , Xiao Hua-liang , Zhou Qi , Han Rui , Chen Hengyi , Wang Haidong , Yang Zhenzhou , Gao Chan , Cai Shangli , He Yong
Published: April 2023

Kaplan-Meier analyses of PFS for patients with normal and elevated ({greater than or equal to}7 pg/ml) baseline IL-6 levels.
Supplementary Table S2: Laboratory Abnormalities from FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia
Authors: Norsworthy Kelly J. , By Kunthel , Subramaniam Sriram , Zhuang Luning , Del Valle Pedro L. , Przepiorka Donna , Shen Yuan-Li , Sheth Christopher M. , Liu Chao , Leong Ruby , Goldberg Kirsten B. , Farrell Ann T. , Pazdur Richard
Published: April 2023

Supplementary Table S2
Supplementary Figure S1: Overall Survival Subpopulation Analysis from FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia
Authors: Norsworthy Kelly J. , By Kunthel , Subramaniam Sriram , Zhuang Luning , Del Valle Pedro L. , Przepiorka Donna , Shen Yuan-Li , Sheth Christopher M. , Liu Chao , Leong Ruby , Goldberg Kirsten B. , Farrell Ann T. , Pazdur Richard
Published: April 2023

Supplementary Figure 1
Online Figure 1 from Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm
Authors: van der Voort Sebastian R. , Incekara Fatih , Wijnenga Maarten M.J. , Kapas Georgios , Gardeniers Mayke , Schouten Joost W. , Starmans Martijn P.A. , Nandoe Tewarie Rishie , Lycklama Geert J. , French Pim J. , Dubbink Hendrikus J. , van den Bent Martin J. , Vincent Arnaud J.P.E. , Niessen Wiro J. , Klein Stefan , Smits Marion
Published: April 2023

Overview of the radiogenomics pipeline
Appendix 3 from Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm
Authors: van der Voort Sebastian R. , Incekara Fatih , Wijnenga Maarten M.J. , Kapas Georgios , Gardeniers Mayke , Schouten Joost W. , Starmans Martijn P.A. , Nandoe Tewarie Rishie , Lycklama Geert J. , French Pim J. , Dubbink Hendrikus J. , van den Bent Martin J. , Vincent Arnaud J.P.E. , Niessen Wiro J. , Klein Stefan , Smits Marion
Published: April 2023

Evaluation metrics
Table S3 from Tumor-Contacted Neutrophils Promote Metastasis by a CD90-TIMP-1 Juxtacrine–Paracrine Loop
Authors: Wang Ying , Chen Jianing , Yang Linbin , Li Jiaqian , Wu Wei , Huang Min , Lin Ling , Su Shicheng
Published: April 2023

Table S3 shows the univariate Cox regression analyses of overall survival.
Suppl Figure 6 from AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival
Authors: Cosimo Emilio , Tarafdar Anuradha , Moles Michael W. , Holroyd Ailsa K. , Malik Natasha , Catherwood Mark A. , Hay Jodie , Dunn Karen M. , Macdonald Alan M. , Guichard Sylvie M. , O'Rourke Declan , Leach Michael T. , Sansom Owen J. , Cosulich Sabina C. , McCaig Alison M. , Michie Alison M.
Published: April 2023

Suppl Figure 6
Suppl Figure 5 from AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival
Authors: Cosimo Emilio , Tarafdar Anuradha , Moles Michael W. , Holroyd Ailsa K. , Malik Natasha , Catherwood Mark A. , Hay Jodie , Dunn Karen M. , Macdonald Alan M. , Guichard Sylvie M. , O'Rourke Declan , Leach Michael T. , Sansom Owen J. , Cosulich Sabina C. , McCaig Alison M. , Michie Alison M.
Published: April 2023

Suppl Figure 5
Suppl Figure 4 from AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival
Authors: Cosimo Emilio , Tarafdar Anuradha , Moles Michael W. , Holroyd Ailsa K. , Malik Natasha , Catherwood Mark A. , Hay Jodie , Dunn Karen M. , Macdonald Alan M. , Guichard Sylvie M. , O'Rourke Declan , Leach Michael T. , Sansom Owen J. , Cosulich Sabina C. , McCaig Alison M. , Michie Alison M.
Published: April 2023

Suppl Figure 4
Suppl Figure 2 from AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival
Authors: Cosimo Emilio , Tarafdar Anuradha , Moles Michael W. , Holroyd Ailsa K. , Malik Natasha , Catherwood Mark A. , Hay Jodie , Dunn Karen M. , Macdonald Alan M. , Guichard Sylvie M. , O'Rourke Declan , Leach Michael T. , Sansom Owen J. , Cosulich Sabina C. , McCaig Alison M. , Michie Alison M.
Published: April 2023

Suppl Figure 2
Supplementary Data from Radiotherapy Eradicates Malignant T Cells and Is Associated with Improved Survival in Early-Stage Mycosis Fungoides
Authors: O'Malley John T. , de Masson Adele , Lowry Elizabeth L. , Giobbie-Hurder Anita , LeBoeuf Nicole R. , Larocca Cecilia , Gehad Ahmed , Seger Edward , Teague Jessica E. , Fisher David C. , Kupper Thomas S. , Devlin Phillip M. , Clark Rachael A.
Published: April 2023

Supplemental Tables S1-S7
Supplementary Data from Radiotherapy Eradicates Malignant T Cells and Is Associated with Improved Survival in Early-Stage Mycosis Fungoides
Authors: O'Malley John T. , de Masson Adele , Lowry Elizabeth L. , Giobbie-Hurder Anita , LeBoeuf Nicole R. , Larocca Cecilia , Gehad Ahmed , Seger Edward , Teague Jessica E. , Fisher David C. , Kupper Thomas S. , Devlin Phillip M. , Clark Rachael A.
Published: April 2023

Figure S2
Supplementary table 1 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment
Authors: Tulotta Claudia , Lefley Diane V. , Freeman Katy , Gregory Walter M. , Hanby Andrew M. , Heath Paul R. , Nutter Faith , Wilkinson J. Mark , Spicer-Hadlington Amy R. , Liu Xinming , Bradbury Steven M.J. , Hambley Lisa , Cookson Victoria , Allocca Gloria , Kruithof de Julio Marianna , Coleman Robert E. , Brown Janet E. , Holen Ingunn , Ottewell Penelope D.
Published: April 2023

Tumour-derived IL-1B predicts distant recurrence and relapse in bone in patients with stage II and III breast cancer.
Supplementary figure legends from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment
Authors: Tulotta Claudia , Lefley Diane V. , Freeman Katy , Gregory Walter M. , Hanby Andrew M. , Heath Paul R. , Nutter Faith , Wilkinson J. Mark , Spicer-Hadlington Amy R. , Liu Xinming , Bradbury Steven M.J. , Hambley Lisa , Cookson Victoria , Allocca Gloria , Kruithof de Julio Marianna , Coleman Robert E. , Brown Janet E. , Holen Ingunn , Ottewell Penelope D.
Published: April 2023

Supplementary figure legends
Table S5 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
Authors: Fang Wenfeng , Ma Yuxiang , Yin Jiani C. , Hong Shaodong , Zhou Huaqiang , Wang Ao , Wang Fufeng , Bao Hua , Wu Xue , Yang Yunpeng , Huang Yan , Zhao Hongyun , Shao Yang W. , Zhang Li
Published: April 2023

Copy number alterations in genes in immune-related pathways in each patient
Supplementary figure 3 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment
Authors: Tulotta Claudia , Lefley Diane V. , Freeman Katy , Gregory Walter M. , Hanby Andrew M. , Heath Paul R. , Nutter Faith , Wilkinson J. Mark , Spicer-Hadlington Amy R. , Liu Xinming , Bradbury Steven M.J. , Hambley Lisa , Cookson Victoria , Allocca Gloria , Kruithof de Julio Marianna , Coleman Robert E. , Brown Janet E. , Holen Ingunn , Ottewell Penelope D.
Published: April 2023

Incubation with high concentrations of exogenous IL-1B modestly increases tumour cell migration and invasion.
Supplementary figure 2 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment
Authors: Tulotta Claudia , Lefley Diane V. , Freeman Katy , Gregory Walter M. , Hanby Andrew M. , Heath Paul R. , Nutter Faith , Wilkinson J. Mark , Spicer-Hadlington Amy R. , Liu Xinming , Bradbury Steven M.J. , Hambley Lisa , Cookson Victoria , Allocca Gloria , Kruithof de Julio Marianna , Coleman Robert E. , Brown Janet E. , Holen Ingunn , Ottewell Penelope D.
Published: April 2023

Stable transfection of breast cancer cells with IL-1B.
Supplementary figure 1 from Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment
Authors: Tulotta Claudia , Lefley Diane V. , Freeman Katy , Gregory Walter M. , Hanby Andrew M. , Heath Paul R. , Nutter Faith , Wilkinson J. Mark , Spicer-Hadlington Amy R. , Liu Xinming , Bradbury Steven M.J. , Hambley Lisa , Cookson Victoria , Allocca Gloria , Kruithof de Julio Marianna , Coleman Robert E. , Brown Janet E. , Holen Ingunn , Ottewell Penelope D.
Published: April 2023

In vivo model of spontaneous human breast cancer metastasis to human bone implants
Supplementary Data S1, S2 from Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors
Authors: Kazi Aslamuzzaman , Xiang Shengyan , Yang Hua , Chen Liwei , Kennedy Perry , Ayaz Muhammad , Fletcher Steven , Cummings Christopher , Lawrence Harshani R. , Beato Francisca , Kang Ya'an , Kim Michael P. , Delitto Andrea , Underwood Patrick W. , Fleming Jason B. , Trevino Jose G. , Hamilton Andrew D. , Sebti Said M.
Published: April 2023

Supplementary Figure 1. FGTI-2734 does not induce apoptosis in wild-type RAS human cancer cells and normal cells; Supplementary Figure 2. FGTI-2734 inhibits in vivo growth of PDXs from pancreatic cancer patients.
Supplementary Materials and Methods from Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma
Authors: Chen Robert , Herrera Alex F. , Hou Jessie , Chen Lu , Wu Jun , Guo Yuming , Synold Timothy W. , Ngo Vu N. , Puverel Sandrine , Mei Matthew , Popplewell Leslie , Yi Shuhua , Song Joo Y. , Tao Shu , Wu Xiwei , Chan Wing C. , Forman Stephen J. , Kwak Larry W. , Rosen Steven T. , Newman Edward M.
Published: April 2023

Supplementary Materials and Methods
Table S4 from A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
Authors: Mita Monica M. , LoRusso Patricia M. , Papadopoulos Kyriakos P. , Gordon Michael S. , Mita Alain C. , Ferraldeschi Roberta , Keer Harold , Oganesian Aram , Su Xiang Yao , Jueliger Simone , Tolcher Anthony W.
Published: April 2023

Table S4 shows descriptive statistics of ASTX660 pharmacokinetic parameters per dose level across cycles and days: pharmacokinetic population
Table S3 from A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
Authors: Mita Monica M. , LoRusso Patricia M. , Papadopoulos Kyriakos P. , Gordon Michael S. , Mita Alain C. , Ferraldeschi Roberta , Keer Harold , Oganesian Aram , Su Xiang Yao , Jueliger Simone , Tolcher Anthony W.
Published: April 2023

Table S3 shows grade {greater than or equal to}3 adverse events (regardless of relationship to study drug) in {greater than or equal to}2 patients in total phase 1 population
Table S2 from A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
Authors: Mita Monica M. , LoRusso Patricia M. , Papadopoulos Kyriakos P. , Gordon Michael S. , Mita Alain C. , Ferraldeschi Roberta , Keer Harold , Oganesian Aram , Su Xiang Yao , Jueliger Simone , Tolcher Anthony W.
Published: April 2023

Table S2 shows adverse events (regardless of relationship to study drug) by preferred term in {greater than or equal to}10% of patients in total phase 1 population
Supplementary Figure 3 from Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma
Authors: Chen Robert , Herrera Alex F. , Hou Jessie , Chen Lu , Wu Jun , Guo Yuming , Synold Timothy W. , Ngo Vu N. , Puverel Sandrine , Mei Matthew , Popplewell Leslie , Yi Shuhua , Song Joo Y. , Tao Shu , Wu Xiwei , Chan Wing C. , Forman Stephen J. , Kwak Larry W. , Rosen Steven T. , Newman Edward M.
Published: April 2023

Supplementary Figure 3
Table S1 from A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
Authors: Mita Monica M. , LoRusso Patricia M. , Papadopoulos Kyriakos P. , Gordon Michael S. , Mita Alain C. , Ferraldeschi Roberta , Keer Harold , Oganesian Aram , Su Xiang Yao , Jueliger Simone , Tolcher Anthony W.
Published: April 2023

Table S1 shows dose levels of ASTX660 by cohort
Figure S3 from A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
Authors: Mita Monica M. , LoRusso Patricia M. , Papadopoulos Kyriakos P. , Gordon Michael S. , Mita Alain C. , Ferraldeschi Roberta , Keer Harold , Oganesian Aram , Su Xiang Yao , Jueliger Simone , Tolcher Anthony W.
Published: April 2023

Figure S3 shows changes in interleukin-8 in plasma from screening thru day 9 at the indicated doses.
Supplementary Figure 4 from Mutation Status of RAS, TP53, and SMAD4 is Superior to Mutation Status of RAS Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases
Authors: Kawaguchi Yoshikuni , Kopetz Scott , Newhook Timothy E. , De Bellis Mario , Chun Yun Shin , Tzeng Ching-Wei D. , Aloia Thomas A. , Vauthey Jean-Nicolas
Published: April 2023

Supplementary Figure 4. Overall survival (OS) by RAS, TP53, and SMAD4 mutation status in 313 patients with unresectable colorectal metastases.
Supplementary Figure 3 from Mutation Status of RAS, TP53, and SMAD4 is Superior to Mutation Status of RAS Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases
Authors: Kawaguchi Yoshikuni , Kopetz Scott , Newhook Timothy E. , De Bellis Mario , Chun Yun Shin , Tzeng Ching-Wei D. , Aloia Thomas A. , Vauthey Jean-Nicolas
Published: April 2023

Supplementary Figure 3. Overall survival (OS) and recurrence-free survival (RFS) by RAS mutation status.
Supplementary Data from Mutation Status of RAS, TP53, and SMAD4 is Superior to Mutation Status of RAS Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases
Authors: Kawaguchi Yoshikuni , Kopetz Scott , Newhook Timothy E. , De Bellis Mario , Chun Yun Shin , Tzeng Ching-Wei D. , Aloia Thomas A. , Vauthey Jean-Nicolas
Published: April 2023

Supplementary Table 1. Genes and codon tested for adequate amplicons Supplementary Table 2. Multivariable hazard ratios (HRs) for OS and RFS by RAS mutation status in 507 patients Supplementary Table 3. Demographic and clinicopathologic characteristics of 313 patients with unresectable colorectal metastases.
Table S4 from Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy
Authors: Xie Feng , Zhang Jianjun , Wang Jiayin , Reuben Alexandre , Xu Wei , Yi Xin , Varn Frederick S. , Ye Yongsheng , Cheng Junwen , Yu Miao , Wang Yue , Liu Yufeng , Xie Mingchao , Du Peng , Ma Ke , Ma Xin , Zhou Penghui , Yang Shengli , Chen Yaobing , Wang Guoping , Xia Xuefeng , Liao Zhongxing , Heymach John V. , Wistuba Ignacio I. , Futreal P. Andrew , Ye Kai , Cheng Chao , Xia Tian
Published: April 2023

Table S4 describes relationship between bench marker gene mutations and clinical benefit from ICI.
Table S2 from Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy
Authors: Xie Feng , Zhang Jianjun , Wang Jiayin , Reuben Alexandre , Xu Wei , Yi Xin , Varn Frederick S. , Ye Yongsheng , Cheng Junwen , Yu Miao , Wang Yue , Liu Yufeng , Xie Mingchao , Du Peng , Ma Ke , Ma Xin , Zhou Penghui , Yang Shengli , Chen Yaobing , Wang Guoping , Xia Xuefeng , Liao Zhongxing , Heymach John V. , Wistuba Ignacio I. , Futreal P. Andrew , Ye Kai , Cheng Chao , Xia Tian
Published: April 2023

Table S2 describes the number of cases in each Genomic Class (GC) across tumor types.
Figure S1-12 from Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy
Authors: Xie Feng , Zhang Jianjun , Wang Jiayin , Reuben Alexandre , Xu Wei , Yi Xin , Varn Frederick S. , Ye Yongsheng , Cheng Junwen , Yu Miao , Wang Yue , Liu Yufeng , Xie Mingchao , Du Peng , Ma Ke , Ma Xin , Zhou Penghui , Yang Shengli , Chen Yaobing , Wang Guoping , Xia Xuefeng , Liao Zhongxing , Heymach John V. , Wistuba Ignacio I. , Futreal P. Andrew , Ye Kai , Cheng Chao , Xia Tian
Published: April 2023

The supplementary figures illustrate Multifactorial deep learning model structures, Correlations of three types of genomic alterations, Immune gene panel profile difference between GCs, Mismatch repair gene mutation frequency of each GC, Gene Set Enrichment Analysis (GSEA) enriched pathways analysis for the stratification, GSEA analysis results of Van Allen's and TCGA melanoma cohorts, Immunotherapy response and prediction survivals of Van Allen's cohort, The mTMB, MSI burden, SCNA burden of Van Allen's cohort in each GC, Deep learning model analysis for combined Van Allen's and Snyder's cohorts, Simple multivariable analysis for combined Van Allen's and Snyder's cohorts, Clinical response analyzed based on gene biomarkers in Van Allen's cohort, Snyder's cohort and combined cohort, Overall survival analyzed based on gene biomarkers in Van Allen's cohort, Snyder's cohort and combined cohort while figures are labeled with S1-12, respectively.
Table S2 from Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study
Authors: Crosby Erika J. , Gwin William , Blackwell Kimberly , Marcom Paul K. , Chang Serena , Maecker Holden T. , Broadwater Gloria , Hyslop Terry , Kim Sungjin , Rogatko Andre , Lubkov Veronica , Snyder Joshua C. , Osada Takuya , Hobeika Amy C. , Morse Michael A. , Lyerly H. Kim , Hartman Zachary C.
Published: April 2023

Concurrent HER2 therapies for each patient for whom CYTOF analysis was done
Figure S2 from Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study
Authors: Crosby Erika J. , Gwin William , Blackwell Kimberly , Marcom Paul K. , Chang Serena , Maecker Holden T. , Broadwater Gloria , Hyslop Terry , Kim Sungjin , Rogatko Andre , Lubkov Veronica , Snyder Joshua C. , Osada Takuya , Hobeika Amy C. , Morse Michael A. , Lyerly H. Kim , Hartman Zachary C.
Published: April 2023

Mutation of HER2 to obscure binding of Trastuzumab and Pertuzumab
Figure S2 from Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma
Authors: Gartrell Robyn D. , Marks Douglas K. , Rizk Emanuelle M. , Bogardus Margaret , Gérard Camille L. , Barker Luke W. , Fu Yichun , Esancy Camden L. , Li Gen , Ji Jiayi , Rui Shumin , Ernstoff Marc S. , Taback Bret , Pabla Sarabjot , Chang Rui , Lee Sandra J. , Krolewski John J. , Morrison Carl , Horst Basil A. , Saenger Yvonne M.
Published: April 2023

Heat map showing relative levels of mRNA expression for each gene, specifying the gene represented by each row.
Supplementary appendix from Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers
Authors: Peters Solange , Stahel Rolf , Bubendorf Lukas , Bonomi Philip , Villegas Augusto , Kowalski Dariusz M. , Baik Christina S. , Isla Dolores , Carpeno Javier De Castro , Garrido Pilar , Rittmeyer Achim , Tiseo Marcello , Meyenberg Christoph , de Haas Sanne , Lam Lisa H. , Lu Michael W. , Stinchcombe Thomas E.
Published: April 2023

Supplementary appendix